Based on the algorithm, PE was excluded and CPTA was withheld in 1,651 patients who either had: no YEARS items and a D-dimer level . 1000 ng/mL; or one or more YEARS items and a D-dimer level 500 ...

Of the 16 patients, 1 did not meet any of the YEARS criteria (0.4% of the 252 patients who met no YEARS criteria) but had a d-dimer level above the prespecified threshold, and 15 met at least one ...

Overall, the Wells rule, the revised Geneva score, and the YEARS algorithm were most efficient (based on the proportion of patients with PE ruled out without the use of imaging) when combined with ...

August 30, 2016 ...

From an efficiency perspective, the authors support the application of strategies with adapted D-dimer thresholds. ... revised Geneva score or the YEARS algorithm, combined with D-dimer testing.

According to a 2022 article, a typical D-dimer level is less than 0.50 mg/L of fibrinogen equivalent units (FEU). A positive D-dimer is 0.50 mg/L or higher, indicating that a person may have blood ...

(HealthDay)—D-dimer unit type should be clarified and laboratories interested in implementing age-adjusted D-dimer (AADD) cut-offs should use only specific D-dimer assays that have been ...

If the D-dimer level is ≥ 1000 ng/mL, CTPA is ordered. For those with one or more items on the modified YEARS protocol, pulmonary embolism can be excluded if the D-dimer test shows a level less than ...

A study published last year showing that patients suspected of having a deep-vein thrombosis could have the condition ruled out if a D-dimer test was negative, has stirred debate. (Correspondence ...

D-dimer is a marker of endogenous fibrinolysis and should therefore be detectable in patients with deep-vein thrombosis. Several studies have shown the D-dimer assay to have a high negative ...

For patients with suspected pulmonary embolism, diagnostic strategies to rule out PE that apply adapted D-dimer thresholds were safe and efficient, even in high-risk patients.Researchers reported ...

Plasma d-dimer levels to rule out pulmonary embolism in hospitalized COVID-19 patients is not the right assay to use, new research suggests. Most patients already have levels greater than 0.05 μg/mL.